LTLuke D. J. Thomson

Luke D. J. Thomson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Luke D. J. Thomson has a total of 63 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Combined supplemental oxygen and mandibular advancement device therapy for obstructive sleep apnoea: a randomised controlled trial

    by Bradley A. Edwards, Luke D.J. Thomson, Daniel Vena, Andrew Gikas, Reza Radmand, Nicole Calianese, Lauren B. Hess, Jinny Collet, Dillon Gilbertson, Natalie V. Lawrence, et al.

    Background: Treatment for obstructive sleep apnoea (OSA) is limited by intolerance to continuous positive airway pressure. While OSA manifests due to both increased pharyngeal collapsibility and ventilatory control instability, randomised trials targeting both components are lacking. We tested whether combining a ventilatory control intervention (supplemental oxygen) with an upper airway mechanical intervention (mandibular advancement device (MAD)) improves treatment efficacy. Methods: In a multicentre randomised crossover trial, 41 patients with moderate-to-severe OSA (apnoea–hypopnoea index (AHI) >20 events·h −1 , scored without desaturation criteria) underwent polysomnography with four single-night interventions: oxygen (4 L·min −1 ), MAD, combination therapy and sham (air). Primary analysis compared percent change in AHI from baseline between combination therapy and MAD monotherapy. Secondary outcomes included arousal index and visual analogue scale for sleep quality (VASSQ). Gold standard baseline pathophysiological traits facilitated mechanistic subgroup analysis. Results: Of 41 randomised patients (14 females:27 males, median (interquartile range) baseline AHI 49 (29, 62) events·h −1 ), 38 completed all interventions. Compared with sham, AHI was lowered with oxygen (estimate: −33 (95% CI −46, −17)%), MAD (−54 (95% CI −64, −41)%) and the combination (−68 (95% CI −77, −57)%); the combination provided a greater reduction than MAD monotherapy (−14 (95% CI −23, −4)%; p=0.009). The combination also improved AHI per 3% desaturation/arousal criteria (−73 (95% CI −81, −62)% versus sham and −17 (95% CI −25, −7)% versus MAD). The combination improved arousal index (−36 (95% CI −43, −27)% versus sham) and VASSQ (+0.98 (95% CI 0.39, 1.58) versus sham), albeit not significantly beyond MAD alone. Effects were greatest in those with higher loop gain and collapsibility. Conclusion: Combining a ventilatory control intervention (supplemental oxygen) with an upper airway intervention (MAD) is a promising approach to markedly attenuate OSA severity beyond that offered by each intervention alone.


  • Open Access

    The effect of M‐current activation on controller gain and obstructive sleep apnoea severity: a randomised controlled trial using flupirtine

    by Luke D. J. Thomson, Shane A. Landry, Andre Arellano, Jinny Collet, Stuart Huddle, Denise M. O'DRiscoll, Dwayne L. Mann, Caroline Beatty, Simon A. Joosten, Garun S. Hamilton, et al.

    Ventilatory control instability, or high loop gain (LG), contributes towards upper airway collapse in approximately one‐third of people with obstructive sleep apnoea (OSA). A high LG can be the product of elevated chemosensitivity (controller gain) and/or an excessive ventilatory output (plant gain). Therapies such as carbonic anhydrase inhibitors (targeting plant gain) have been shown to reduce OSA severity; however, there is a lack of viable pharmacological options targeting controller gain. This study investigated the effect of flupirtine (400 mg), a KCNQ potassium channel opener, on LG and OSA severity in fifteen moderate‐to‐severe OSA patients through a randomised, double‐blind, placebo‐controlled trial. Despite the hypothesised potential of flupirtine to reduce LG by attenuating chemosensory activity, our findings revealed no significant effect on LG and OSA severity. The lack of overall efficacy of flupirtine is most likely due to multifactorial nature of OSA and the challenges of its management. Our findings suggest a need for a nuanced understanding of OSA pathogenesis and caution against the use of flupirtine in managing OSA. While, pharmacological modulation of ionic channels within the ventilatory control system presents a promising strategy, given the plethora of robust targets available, it remains to be determined whether an effective treatment can capitalise on a single predominant ionic current ubiquitous throughout the ventilatory system, or if a more successful approach necessitates the simultaneous modulation of multiple targets. This research enhances our understanding of the ventilatory control system's contribution to OSA and the complexity of finding a one‐size‐fits‐all treatment. image Key points: Around one‐third of obstructive sleep apnoea (OSA) cases involve an unstable control of breathing, leading to airway collapse. This research examined whether the drug flupirtine could stabilise breathing control and reduce OSA severity in 15 patients. Flupirtine, which was expected to improve breathing control by reducing chemosensitivity, showed no significant benefit for OSA. While targeting ionic channels in the breathing system is promising, the search for an effective OSA treatment may require addressing multiple targets simultaneously.


  • Obstructive Sleep Apnea Is a Distinct Physiological Endotype in Individuals with Comorbid Insomnia and Sleep Apnea

    by Elliot J. Brooker, Shane A. Landry, Luke D. J. Thomson, Garun S. Hamilton, Pedro R. Genta, Sean P. A. Drummond, Bradley A. Edwards

    Rationale: With up to 40% of individuals with either insomnia or obstructive sleep apnea (OSA) demonstrating clinically significant symptoms of the other disorder, the high degree of comorbidity among the two most common sleep disorders suggests a bidirectional relationship and/or shared underpinnings. Although the presence of insomnia disorder is believed to influence the underlying pathophysiology of OSA, this influence is yet to be examined directly. Objectives: To investigate whether the four OSA endotypes (upper airway collapsibility, muscle compensation, loop gain, and the arousal threshold) are different in patients with OSA with and without comorbid insomnia disorder. Methods: Using the ventilatory flow pattern captured from routine polysomnography, the four OSA endotypes were measured in 34 patients with OSA who met the diagnostic criteria for insomnia disorder (COMISA) and 34 patients with OSA without insomnia (OSA only). Patients demonstrated mild-to-severe OSA (apnea–hypopnea index, 25.8 ± 2.0 events/h) and were individually matched according to age (50.2 ± 1.5 yr), sex (42 male: 26 female), and body mass index (29.3 ± 0.6 kg/m2). Results: Compared with patients with OSA without comorbid insomnia, patients with COMISA demonstrated significantly lower respiratory arousal thresholds (128.9 [118.1 to 137.1] vs. 147.7 [132.3 to 165.0] % eupneic ventilation (V̇eupnea); U = 261; 95% confidence interval [CI], −38.3 to −13.9; d = 1.1; P < 0.001), less collapsible upper airways (88.2 [85.5 to 94.6] vs. 72.9 [64.7 to 79.2] % V̇eupnea; U = 1081; 95% CI, 14.0 to 26.7; d = 2.3; P < 0.001), and more stable ventilatory control (i.e., lower loop gain: 0.51 [0.44 to 0.56] vs. 0.58 [0.49 to 0.70]; U = 402; 95% CI, −0.2 to −0.01; d = 0.05; P = 0.03). Muscle compensation was similar between groups. Moderated linear regression revealed that the arousal threshold moderated the relationship between collapsibility and OSA severity in patients with COMISA but not in patients with OSA only. Conclusions: A low arousal threshold is an overrepresented endotypic trait in individuals with COMISA and may exhibit a greater relative contribution to OSA pathogenesis in these patients. Contrastingly, the prevalence of a highly collapsible upper airway in COMISA was low, suggesting that anatomical predisposition may contribute less to OSA development in COMISA. Based on our findings, we theorize that conditioned hyperarousal perpetuating insomnia may translate to a reduced arousal threshold to respiratory events, thereby increasing the risk or severity of OSA. Therapies that target increased nocturnal hyperarousal (e.g., through cognitive behavior therapy for insomnia) may be effective in individuals with COMISA. Clinical trial registered with the Australian and New Zealand Clinical Trial Registry (ACTRN12616000586415).


  • A Randomised Controlled Trial Examining the Combined Impact of Acetazolamide and Dronabinol for the Treatment of Obstructive Sleep Apnoea

    by L.D.J. Thomson, T. Rankin, S. Mehra, M.T. Naughton, T. Roebuck, E. McDermott, A. Pattichis, R. Smith, J. Germaine, R. Walsh, et al.

  • Oronasal vs Nasal Masks

    by Shane A. Landry, Dwayne L. Mann, Richard Beare, Richard McIntyre, Caroline Beatty, Luke D.J. Thomson, Jinny Collet, Simon A. Joosten, Garun S. Hamilton, Bradley A. Edwards


  • Open Access

    Examining the impact of multilevel upper airway surgery on the obstructive sleep apnoea endotypes and their utility in predicting surgical outcomes

    by Ai‐Ming Wong, Shane A. Landry, Simon A. Joosten, Luke D. J. Thomson, Anthony Turton, Jeremy Stonehouse, Darren R. Mansfield, Glen Burgess, Andrew Hays, Scott A. Sands, et al.

    Background and objective: Upper airway surgery for obstructive sleep apnoea (OSA) is an alternative treatment for patients who are intolerant of continuous positive airway pressure (CPAP). However, upper airway surgery has variable treatment efficacy with no reliable predictors of response. While we now know that there are several endotypes contributing to OSA (i.e., upper airway collapsibility, airway muscle response/compensation, respiratory arousal threshold and loop gain), no study to date has examined: (i) how upper airway surgery affects all four OSA endotypes, (ii) whether knowledge of baseline OSA endotypes predicts response to surgery and (iii) whether there are any differences when OSA endotypes are measured using the CPAP dial‐down or clinical polysomnographic (PSG) methods.Methods: We prospectively studied 23 OSA patients before and ≥3 months after multilevel upper airway surgery. Participants underwent clinical and research PSG to measure OSA severity (apnoea–hypopnoea index [AHI]) and endotypes (measured in supine non‐rapid eye movement [NREM]). Values are presented as mean ± SD or median (interquartile range).Results: Surgery reduced the AHITotal (38.7 [23.4 to 79.2] vs. 22.0 [13.3 to 53.5] events/h; p = 0.009). There were no significant changes in OSA endotypes, however, large but variable improvements in collapsibility were observed (CPAP dial‐down method: ∆1.9 ± 4.9 L/min, p = 0.09, n = 21; PSG method: ∆3.4 [−2.8 to 49.0]%Veupnoea, p = 0.06, n = 20). Improvement in collapsibility strongly correlated with improvement in AHI (%∆AHISupineNREM vs. ∆collapsibility: p < 0.005; R2 = 0.46–0.48). None of the baseline OSA endotypes predicted response to surgery.Conclusion: Surgery unpredictably alters upper airway collapsibility but does not alter the non‐anatomical endotypes. There are no baseline predictors of response to surgery.


  • The Effect of Hypopnea Scoring on the Arousal Threshold in Patients with Obstructive Sleep Apnea

    by Luke D. J. Thomson, Shane A. Landry, Rebecca Singleton, Ai-Ming Wong, Simon A. Joosten, Caroline J. Beatty, Danny J. Eckert, Atul Malhotra, Garun S. Hamilton, Bradley A. Edwards


  • Open Access

    Laboratory performance of oronasal CPAP and adapted snorkel masks to entrain oxygen and CPAP

    by Shane A. Landry, Dwayne L. Mann, Lee Djumas, Ludovico Messineo, Philip I. Terrill, Luke D.J. Thomson, Caroline J. Beatty, Garun S. Hamilton, Darren Mansfield, Bradley A. Edwards, et al.


  • Effect of Hypopnea Scoring Criteria on Noninvasive Assessment of Loop Gain and Surgical Outcome Prediction

    by Shane A. Landry, Simon A. Joosten, Luke D. J. Thomson, Anthony Turton, Ai-Ming Wong, Paul Leong, Philip I. Terrill, Dwayne Mann, Scott A. Sands, Garun S. Hamilton, et al.

    Rationale: Unstable ventilatory control (high loop gain) is a causal factor in the development of obstructive sleep apnea. Methods for quantifying loop gain using polysomnography have been developed that predict favorable responses to upper airway surgery. However, this method is reliant on respiratory event scoring and hence may be affected by hypopnea scoring criteria. Objectives: To determine to what extent differences in hypopnea scoring influence loop gain measurement. Methods: We performed a retrospective analysis of 46 polysomnograms before and after upper airway surgery. Polysomnograms were rescored according to three different American Academy of Sleep Medicine hypopnea definitions (2007Alternative, 2012Recommended, and 2012Acceptable criteria). Loop gain and apnea–hypopnea indexes (AHIs) were compared between criteria using linear regression and Bland-Altman limits of agreement (LOA). Responders to surgery were classified by a 50% or greater reduction in AHI and AHIpostsurgery less than 10 events per hour. Responders were determined separately for each American Academy of Sleep Medicine criterion. Receiver operating characteristic curve analysis predicting surgical outcome was performed for each loop gain measurement derived from each criterion. Results: A near-perfect agreement was found between loop gains derived using the 2007Alternative and 2012Recommended criteria (r2 = 0.99; bias = −0.003; LOA, −0.016 to 0.010). Greater variability was found for 2012Acceptable compared to the 2007Alternative (r2 = 0.70; bias = −0.015; LOA, −0.099 to 0.070) and 2012Recommended (r2 = 0.69; bias = +0.018; LOA, −0.068 to 0.104) criteria. Both 2007Alternative and 2012Recommended loop gains significantly predicted surgical response with similar areas under the curve (AUCs; 2007Alternative AUC = 0.86 [95% confidence interval (CI), 0.75–0.97]; 2012Recommended AUC = 0.84 [95% CI, 0.71–0.97]). 2012Acceptable loop gains were a poor predictor of surgical response (AUC = 0.62 [95% CI, 0.43–0.80]). Conclusions: Loop gain measured noninvasively by polysomnography can be influenced by respiratory event scoring. We recommend caution when using the 2012Acceptable criteria with this method, because such findings may not be directly generalizable to other loop gain values derived from other scoring criteria.